Beam Therapeutics (BEAM) EBT (2019 - 2026)

Beam Therapeutics (BEAM) has reported EBT for 8 consecutive years, with -$98.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 10.25% year-over-year to -$98.3 million; the TTM figure through Mar 2026 stood at -$69.0 million (up 82.19% YoY), while the FY2025 annual figure was -$80.0 million, up 78.77% from the prior year.
• EBT retreated to -$98.3 million in Q1 2026 per BEAM's latest filing, from $244.3 million in the prior quarter.
• Across five years, EBT topped out at $244.3 million in Q4 2025 and bottomed at -$176.2 million in Q2 2022.
• Historically, EBT has averaged -$62.6 million across 5 years, with a median of -$92.7 million in 2024.
• Annual changes were most pronounced in 2022 — EBT sank 190.44% — and 2023, when it soared 485.99%.
• Beam Therapeutics' EBT stood at -$37.3 million in 2022, then jumped by 485.99% to $144.2 million in 2023, then plunged by 162.67% to -$90.4 million in 2024, then soared by 370.38% to $244.3 million in 2025, then tumbled by 140.24% to -$98.3 million in 2026.
• Business Quant data shows BEAM's EBT at -$98.3 million in Q1 2026, $244.3 million in Q4 2025, and -$112.7 million in Q3 2025.